These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3257902)

  • 21. Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
    Naito K; Pellis NR; Kahan BD
    Cell Immunol; 1988 Jan; 111(1):216-34. PubMed ID: 3257414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rescue of the tumor-specific immune response of aged mice in vitro.
    Urban JL; Schreiber H
    J Immunol; 1984 Jul; 133(1):527-34. PubMed ID: 6609995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
    Zangemeister-Wittke U; Schirrmacher V
    Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
    Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
    Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
    Shu S; Rosenberg SA
    J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S; Naito K; Kahan BD; Pellis NR
    Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The C57BL/6 nude, beige mouse: a model of combined T cell and NK effector cell immunodeficiency.
    Pflumio F; Fonteneau P; Gavériaux C; Cammisuli S; Loor F
    Cell Immunol; 1989 Apr; 120(1):218-29. PubMed ID: 2784719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ly-5 molecular forms in congenitally immunodeficient mice.
    Pierotti MA; Traversari C; Ballinari D; Borrello MG; Parmiani G
    Exp Clin Immunogenet; 1984; 1(2):75-82. PubMed ID: 6400994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune surveillance against a solid tumor fails because of immunological ignorance.
    Ochsenbein AF; Klenerman P; Karrer U; Ludewig B; Pericin M; Hengartner H; Zinkernagel RM
    Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2233-8. PubMed ID: 10051624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
    Kern DE; Klarnet JP; Jensen MC; Greenberg PD
    J Immunol; 1986 Jun; 136(11):4303-10. PubMed ID: 2422280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
    Moser M; Sharrow SO; Shearer GM
    J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide.
    Mescher MF; Rogers JD
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):102-12. PubMed ID: 8732693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of syngeneic tumor (Meth A fibrosarcoma) from mice by adoptive immunotherapy of immunized spleen cells induced by Corynebacterium parvum-pyridine extract residue.
    Mukai K; Horimi T; Orita K
    Acta Med Okayama; 1988 Dec; 42(6):301-10. PubMed ID: 3266420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of variant and parental-cross-protective immunity to immunogenic variants of a murine fibrosarcoma using the local adoptive transfer assay.
    Simcik W; Sheu TL; LeGrue SJ
    Cancer Immunol Immunother; 1989; 30(4):219-26. PubMed ID: 2598191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
    Hines DL
    Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asialo-GM1-positive T killer cells are generated in F1 mice injected with parental spleen cells.
    Knobloch C; Dennert G
    J Immunol; 1988 Feb; 140(3):744-9. PubMed ID: 2448375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MHC-II-independent CD4+ T cells induce colitis in immunodeficient RAG-/- hosts.
    Trobonjaca Z; Leithäuser F; Möller P; Bluethmann H; Koezuka Y; MacDonald HR; Reimann J
    J Immunol; 2001 Mar; 166(6):3804-12. PubMed ID: 11238623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.